During the last session, P3 Health Partners Inc (NASDAQ:PIII)’s traded shares were 2.21 million, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $0.20, reflecting an intraday loss of -3.37% or -$0.01. The company’s market capitalization is $73.13M, and the average intraday trading volume over the past 10 days was 0.99 million shares, and the average trade volume was 735.07K shares over the past three months.
P3 Health Partners Inc (PIII) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. PIII has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
P3 Health Partners Inc (NASDAQ:PIII) trade information
P3 Health Partners Inc (PIII) registered a -3.37% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.37% in intraday trading to $0.20, hitting a weekly high. The stock’s 5-day price performance is -18.45%, and it has moved by -53.68% in 30 days. Based on these gigs, the overall price performance for the year is -82.87%. The short interest in P3 Health Partners Inc (NASDAQ:PIII) is 0.96 million shares and it means that shorts have 1.21 day(s) to cover.
P3 Health Partners Inc (PIII) estimates and forecasts
Statistics show that P3 Health Partners Inc has underperformed its competitors in share price, compared to the industry in which it operates. P3 Health Partners Inc (PIII) shares have gone down -59.40% during the last six months, with a year-to-date growth rate less than the industry average at -6.35% against 25.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 50.00% this quarter and then jump 6.25% in the quarter after that. In the rating firms’ projections, revenue will increase 19.13% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 378.88M as predicted by 4 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 407.15M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 346.86M and 388.49M respectively. In this case, analysts expect current quarter sales to grow by 9.23% and then jump by 4.80% in the coming quarter.
While earnings are projected to return 11.11% in 2024.
PIII Dividends
P3 Health Partners Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
P3 Health Partners Inc (NASDAQ:PIII)’s Major holders
P3 Health Partners Inc insiders own 23.20% of total outstanding shares while institutional holders control 24.99%, with the float percentage being 32.53%. ALYESKA INVESTMENT GROUP, L.P. is the largest shareholder of the company, while 69.0 institutions own stock in it. As of 2024-06-30, the company held over 15.95 million shares (or 13.4152% of all shares), a total value of $7.18 million in shares.
The next largest institutional holding, with 7.9 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 6.645% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.56 million.
